BC
BBIO icon

Bayforest Capital’s BridgeBio Pharma BBIO Stock Holding History

Bayforest Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Buy
2,689
+775
+40% +$54.3K 0.19% 177
2026
Q1 		$142K Sell
1,914
-320
-14% -$23.2K 0.16% 239
2025
Q4 		$171K Buy
+2,234
New +$147K 0.13% 330
2025
Q3 		– Sell
-8,552
Closed -$369K – 736
2025
Q2 		$369K Buy
+8,552
New +$311K 0.16% 260

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Bayforest Capital's BBIO Position: Q2 2026 in Review

Bayforest Capital increased its BridgeBio Pharma (BBIO) stake by 40% in Q2 2026, buying an estimated $54.3K and bringing the position to 2,689 shares worth $200K. The position accounts for 0.19% of the portfolio, ranked #177.

Bayforest Capital first reported a position in BBIO in Q2 2025 and has held it in 4 quarters since. The position peaked at $369K in Q2 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Bayforest Capital held 2,689 shares of BridgeBio Pharma worth $200K as of Q2 2026.
  • Bayforest Capital bought 775 BridgeBio Pharma shares in Q2 2026, an estimated $54.3K.
  • BridgeBio Pharma made up 0.19% of Bayforest Capital's portfolio in Q2 2026, its #177 holding.
  • Bayforest Capital first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 4 quarters since.
  • Bayforest Capital's BridgeBio Pharma position peaked at $369K in Q2 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.